Key result
A paradigm shift in bioprosthetic heart valve development is needed, focusing on immune responses, inflammation, and new engineering approaches to improve longevity, especially for younger patients.
Highlights the need for a paradigm shift in bioprosthetic heart valve development, focusing on immune responses and inflammation to prevent rapid degeneration.
Answers are grounded in this paper and cite their sources.
May warrant individualized valve selection and monitoring in younger patients; leaves open optimal immune-targeted engineering strategies pending prospective trials.
More than 250,000 bioprosthetic heart valves are being implanted annually. Although the majority of recipients are elderly developed-world patients, the most urgent need for tissue valves is in younger patients, where rapid degeneration of contemporary prostheses remains a serious obstacle. After decades of empirical and mostly futile attempts to extend the longevity of tissue valve prostheses, new insights and solutions are on the horizon. Aetiologically, a shift of focus from mineralization to immune responses and inflammation emerges. On the development side, new engineering approaches to both selective extraction of tissue components and cross-links are increasingly defining the new direction. In order to dramatically improve the performance of bioprosthetic heart valves, these new developments need to lead to a broad consensus for a paradigm shift in a hitherto rather stagnant field of medical research.
No takes yet. Share an insight, caveat, or question.
Zilla et al. (2004) conducted a review in Valvular heart disease. Bioprosthetic heart valves was evaluated. A paradigm shift in bioprosthetic heart valve development is needed, focusing on immune responses, inflammation, and new engineering approaches to improve longevity, especially for younger patients.
Synapse has enriched 10 related papers. Consider them for comparative context: